Glutamate-mediated excitotoxicity in schizophrenia: A review

Eric Plitman, Shinichiro Nakajima, Camilo de la Fuente-Sandoval, Philip Gerretsen, M. Mallar Chakravarty, Jane Kobylianskii, Jun Ku Chung, Fernando Caravaggio, Yusuke Iwata, Gary Remington, Ariel Graff-Guerrero

研究成果: Review article

57 引用 (Scopus)

抄録

Findings from neuroimaging studies in patients with schizophrenia suggest widespread structural changes although the mechanisms through which these changes occur are currently unknown. Glutamatergic activity appears to be increased in the early phases of schizophrenia and may contribute to these structural alterations through an excitotoxic effect. The primary aim of this review was to describe the possible role of glutamate-mediated excitotoxicity in explaining the presence of neuroanatomical changes within schizophrenia. A Medline® literature search was conducted, identifying English language studies on the topic of glutamate-mediated excitotoxicity in schizophrenia, using the terms "schizophreni*" and "glutam*" and (("MRS" or "MRI" or "magnetic resonance") or ("computed tomography" or "CT")). Studies concomitantly investigating glutamatergic activity and brain structure in patients with schizophrenia were included. Results are discussed in the context of findings from preclinical studies. Seven studies were identified that met the inclusion criteria. These studies provide inconclusive support for the role of glutamate-mediated excitotoxicity in the occurrence of structural changes within schizophrenia, with the caveat that there is a paucity of human studies investigating this topic. Preclinical data suggest that an excitotoxic effect may occur as a result of a paradoxical increase in glutamatergic activity following N-methyl-d-aspartate receptor hypofunction. Based on animal literature, glutamate-mediated excitotoxicity may account for certain structural changes present in schizophrenia, but additional human studies are required to substantiate these findings. Future studies should adopt a longitudinal design and employ magnetic resonance imaging techniques to investigate whether an association between glutamatergic activity and structural changes exists in patients with schizophrenia.

元の言語English
ページ(範囲)1591-1605
ページ数15
ジャーナルEuropean Neuropsychopharmacology
24
発行部数10
DOI
出版物ステータスPublished - 2014 10 1

Fingerprint

Glutamic Acid
Schizophrenia
Neuroimaging
Magnetic Resonance Spectroscopy
Language
Tomography
Magnetic Resonance Imaging
Brain

ASJC Scopus subject areas

  • Pharmacology
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Pharmacology (medical)

これを引用

Plitman, E., Nakajima, S., de la Fuente-Sandoval, C., Gerretsen, P., Chakravarty, M. M., Kobylianskii, J., ... Graff-Guerrero, A. (2014). Glutamate-mediated excitotoxicity in schizophrenia: A review. European Neuropsychopharmacology, 24(10), 1591-1605. https://doi.org/10.1016/j.euroneuro.2014.07.015

Glutamate-mediated excitotoxicity in schizophrenia : A review. / Plitman, Eric; Nakajima, Shinichiro; de la Fuente-Sandoval, Camilo; Gerretsen, Philip; Chakravarty, M. Mallar; Kobylianskii, Jane; Chung, Jun Ku; Caravaggio, Fernando; Iwata, Yusuke; Remington, Gary; Graff-Guerrero, Ariel.

:: European Neuropsychopharmacology, 巻 24, 番号 10, 01.10.2014, p. 1591-1605.

研究成果: Review article

Plitman, E, Nakajima, S, de la Fuente-Sandoval, C, Gerretsen, P, Chakravarty, MM, Kobylianskii, J, Chung, JK, Caravaggio, F, Iwata, Y, Remington, G & Graff-Guerrero, A 2014, 'Glutamate-mediated excitotoxicity in schizophrenia: A review', European Neuropsychopharmacology, 巻. 24, 番号 10, pp. 1591-1605. https://doi.org/10.1016/j.euroneuro.2014.07.015
Plitman E, Nakajima S, de la Fuente-Sandoval C, Gerretsen P, Chakravarty MM, Kobylianskii J その他. Glutamate-mediated excitotoxicity in schizophrenia: A review. European Neuropsychopharmacology. 2014 10 1;24(10):1591-1605. https://doi.org/10.1016/j.euroneuro.2014.07.015
Plitman, Eric ; Nakajima, Shinichiro ; de la Fuente-Sandoval, Camilo ; Gerretsen, Philip ; Chakravarty, M. Mallar ; Kobylianskii, Jane ; Chung, Jun Ku ; Caravaggio, Fernando ; Iwata, Yusuke ; Remington, Gary ; Graff-Guerrero, Ariel. / Glutamate-mediated excitotoxicity in schizophrenia : A review. :: European Neuropsychopharmacology. 2014 ; 巻 24, 番号 10. pp. 1591-1605.
@article{c21b97235eaf46c7a67aa8da5e714066,
title = "Glutamate-mediated excitotoxicity in schizophrenia: A review",
abstract = "Findings from neuroimaging studies in patients with schizophrenia suggest widespread structural changes although the mechanisms through which these changes occur are currently unknown. Glutamatergic activity appears to be increased in the early phases of schizophrenia and may contribute to these structural alterations through an excitotoxic effect. The primary aim of this review was to describe the possible role of glutamate-mediated excitotoxicity in explaining the presence of neuroanatomical changes within schizophrenia. A Medline{\circledR} literature search was conducted, identifying English language studies on the topic of glutamate-mediated excitotoxicity in schizophrenia, using the terms {"}schizophreni*{"} and {"}glutam*{"} and (({"}MRS{"} or {"}MRI{"} or {"}magnetic resonance{"}) or ({"}computed tomography{"} or {"}CT{"})). Studies concomitantly investigating glutamatergic activity and brain structure in patients with schizophrenia were included. Results are discussed in the context of findings from preclinical studies. Seven studies were identified that met the inclusion criteria. These studies provide inconclusive support for the role of glutamate-mediated excitotoxicity in the occurrence of structural changes within schizophrenia, with the caveat that there is a paucity of human studies investigating this topic. Preclinical data suggest that an excitotoxic effect may occur as a result of a paradoxical increase in glutamatergic activity following N-methyl-d-aspartate receptor hypofunction. Based on animal literature, glutamate-mediated excitotoxicity may account for certain structural changes present in schizophrenia, but additional human studies are required to substantiate these findings. Future studies should adopt a longitudinal design and employ magnetic resonance imaging techniques to investigate whether an association between glutamatergic activity and structural changes exists in patients with schizophrenia.",
keywords = "Excitotoxicity, Glutamate, Glutamine, MRS, Psychosis, Schizophrenia",
author = "Eric Plitman and Shinichiro Nakajima and {de la Fuente-Sandoval}, Camilo and Philip Gerretsen and Chakravarty, {M. Mallar} and Jane Kobylianskii and Chung, {Jun Ku} and Fernando Caravaggio and Yusuke Iwata and Gary Remington and Ariel Graff-Guerrero",
year = "2014",
month = "10",
day = "1",
doi = "10.1016/j.euroneuro.2014.07.015",
language = "English",
volume = "24",
pages = "1591--1605",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier",
number = "10",

}

TY - JOUR

T1 - Glutamate-mediated excitotoxicity in schizophrenia

T2 - A review

AU - Plitman, Eric

AU - Nakajima, Shinichiro

AU - de la Fuente-Sandoval, Camilo

AU - Gerretsen, Philip

AU - Chakravarty, M. Mallar

AU - Kobylianskii, Jane

AU - Chung, Jun Ku

AU - Caravaggio, Fernando

AU - Iwata, Yusuke

AU - Remington, Gary

AU - Graff-Guerrero, Ariel

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Findings from neuroimaging studies in patients with schizophrenia suggest widespread structural changes although the mechanisms through which these changes occur are currently unknown. Glutamatergic activity appears to be increased in the early phases of schizophrenia and may contribute to these structural alterations through an excitotoxic effect. The primary aim of this review was to describe the possible role of glutamate-mediated excitotoxicity in explaining the presence of neuroanatomical changes within schizophrenia. A Medline® literature search was conducted, identifying English language studies on the topic of glutamate-mediated excitotoxicity in schizophrenia, using the terms "schizophreni*" and "glutam*" and (("MRS" or "MRI" or "magnetic resonance") or ("computed tomography" or "CT")). Studies concomitantly investigating glutamatergic activity and brain structure in patients with schizophrenia were included. Results are discussed in the context of findings from preclinical studies. Seven studies were identified that met the inclusion criteria. These studies provide inconclusive support for the role of glutamate-mediated excitotoxicity in the occurrence of structural changes within schizophrenia, with the caveat that there is a paucity of human studies investigating this topic. Preclinical data suggest that an excitotoxic effect may occur as a result of a paradoxical increase in glutamatergic activity following N-methyl-d-aspartate receptor hypofunction. Based on animal literature, glutamate-mediated excitotoxicity may account for certain structural changes present in schizophrenia, but additional human studies are required to substantiate these findings. Future studies should adopt a longitudinal design and employ magnetic resonance imaging techniques to investigate whether an association between glutamatergic activity and structural changes exists in patients with schizophrenia.

AB - Findings from neuroimaging studies in patients with schizophrenia suggest widespread structural changes although the mechanisms through which these changes occur are currently unknown. Glutamatergic activity appears to be increased in the early phases of schizophrenia and may contribute to these structural alterations through an excitotoxic effect. The primary aim of this review was to describe the possible role of glutamate-mediated excitotoxicity in explaining the presence of neuroanatomical changes within schizophrenia. A Medline® literature search was conducted, identifying English language studies on the topic of glutamate-mediated excitotoxicity in schizophrenia, using the terms "schizophreni*" and "glutam*" and (("MRS" or "MRI" or "magnetic resonance") or ("computed tomography" or "CT")). Studies concomitantly investigating glutamatergic activity and brain structure in patients with schizophrenia were included. Results are discussed in the context of findings from preclinical studies. Seven studies were identified that met the inclusion criteria. These studies provide inconclusive support for the role of glutamate-mediated excitotoxicity in the occurrence of structural changes within schizophrenia, with the caveat that there is a paucity of human studies investigating this topic. Preclinical data suggest that an excitotoxic effect may occur as a result of a paradoxical increase in glutamatergic activity following N-methyl-d-aspartate receptor hypofunction. Based on animal literature, glutamate-mediated excitotoxicity may account for certain structural changes present in schizophrenia, but additional human studies are required to substantiate these findings. Future studies should adopt a longitudinal design and employ magnetic resonance imaging techniques to investigate whether an association between glutamatergic activity and structural changes exists in patients with schizophrenia.

KW - Excitotoxicity

KW - Glutamate

KW - Glutamine

KW - MRS

KW - Psychosis

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84907983364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907983364&partnerID=8YFLogxK

U2 - 10.1016/j.euroneuro.2014.07.015

DO - 10.1016/j.euroneuro.2014.07.015

M3 - Review article

C2 - 25159198

AN - SCOPUS:84907983364

VL - 24

SP - 1591

EP - 1605

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 10

ER -